In addition, the uses of the original formulation results in higher ferritin and TSAT levels despite the lower dose of IV iron.
Conclusions The iron and ESA requirements are lower with the original IV iron compared to the generic drug. The mortality rate was similar for both periods. After the switch, the transferrin saturation ratio (TSAT) and serum ferritin levels rose by 6.8%(p<0.001) and 12.4%(p = 0.001), respectively. The erythropoietin resistance index declined from 8.4☗.7 to 7.4☖.7 IU/kg/week/g/dl after the switch from the generic to the original drug (p = 0.001). Results To maintain the same haemoglobin (Hb) levels after switching from the generic to the original formulation, the requirements for IV iron doses were reduced by 34.3% (from 52.8☓3.9 to 34.7☓1.8mg/week, p<0.001), and the ESA doses were also decreased by 12.5% (from 30.6☒3.6 to 27☒1μg/week, p<0.001). Anaemia parameters and doses of ESA and IV iron were prospectively recorded before and after the switch from generic to original IV iron. Methods A total of 342 patients were included, and the follow-up period was 56 weeks for each formulation. We evaluated the changes that were induced after switching from a generic IV iron to an original formulation in a stable, prevalent haemodialysis (HD) population. The clinical efficacy of generic IV iron compared to the original formulation is controversial. The appropriate use of intravenous (IV) iron is essential to minimise the requirements for erythropoiesis-stimulating agents (ESAs).
0 kommentar(er)
